Novo Nordisk A/S Target of Unusually High Options Trading (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) was the target of unusually large options trading activity on Thursday. Traders acquired 77,823 put options on the company. This is an increase of 131% compared to the typical daily volume of 33,745 put options.

Hedge Funds Weigh In On Novo Nordisk A/S

Hedge funds have recently bought and sold shares of the stock. Natixis Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after buying an additional 80,070 shares in the last quarter. Zions Bancorporation N.A. grew its stake in Novo Nordisk A/S by 57.0% in the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after acquiring an additional 6,726 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in Novo Nordisk A/S by 14.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock valued at $34,463,000 after acquiring an additional 37,346 shares during the last quarter. LRI Investments LLC lifted its stake in shares of Novo Nordisk A/S by 103.4% during the 3rd quarter. LRI Investments LLC now owns 12,884 shares of the company’s stock worth $1,534,000 after purchasing an additional 6,550 shares during the period. Finally, Destination Wealth Management boosted its holdings in shares of Novo Nordisk A/S by 5.8% during the third quarter. Destination Wealth Management now owns 158,898 shares of the company’s stock worth $18,920,000 after purchasing an additional 8,780 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 0.3 %

NVO stock opened at $87.65 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 12 month low of $81.50 and a 12 month high of $148.15. The firm has a market capitalization of $393.33 billion, a PE ratio of 28.37, a P/E/G ratio of 1.37 and a beta of 0.40. The company’s 50 day simple moving average is $106.55 and its 200-day simple moving average is $123.67.

Analyst Upgrades and Downgrades

Several analysts recently commented on NVO shares. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 21st. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.